Bone Marrow Transplant Complications Clinical Trial
Official title:
Vaginal Microbiome and the Risk of Vulvovaginal Graft Versus Host Disease Following Hematopoietic Stem Cell Transplantation
Allogeneic stem cell transplantation (also termed "bone marrow transplantation") involves transferring stem cells from a healthy person (the donor) to the patient, after high-intensity chemotherapy or radiation, given to destroy any remaining cancer cells in the body. When a transplant is successful, the donor stem cells replace the original cells in the bone marrow. It may provide the only long-term cure of the patient's disease. Of transplant-related complications, graft-versus-host disease (GVHD) is one of the most important complications. GVHD arises from donor immune cells, that identify the recipient's (the patien's) cells as foreign and attack them. Approximately half of women undergoing transplantation will experience GVHD involving the genitalia (i.e., the vulva and vagina), termed vulvovaginal GVHD (VV-GVHD). VV-GVHD may cause irreversible anatomical changes, including complete vaginal obliteration, and not surprisingly, it has a severe impact on patients' quality of life and sexual function. This complication is unpredictable and non-preventable by the usual immunosuppressive treatment given to patients. Frequent gynecological examinations and prolonged follow-up of transplanted women are needed, to allow early diagnosis and prevention of harmful results of VV-GVHD. This follow-up adds inconvenience and anxiety to the patients. The suggested study aims to evaluate a possible association between vaginal microorganisms (the "microbiome") to the progress of VV-GVHD. Finding such association may allow prediction of VV-GVHD progress, a better understanding of the development of VV-GVHD and a potential to develop interventions for the treatment and prevention of VV-GVHD.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
| Recruiting |
NCT03818334 -
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05895201 -
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
|
Phase 1/Phase 2 | |
| Completed |
NCT04687982 -
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
|
N/A | |
| Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
| Completed |
NCT03858530 -
Ultrasound Elastography to Predict Development of SOS
|
Phase 4 | |
| Recruiting |
NCT04313036 -
5-day Defibrotide Treatment for Hepatic SOS/VOD
|
Phase 2 | |
| Completed |
NCT03200626 -
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
|
||
| Recruiting |
NCT05709912 -
Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant
|
N/A | |
| Completed |
NCT05175222 -
Assessment of Efficacy of LightWalker (Nd:Yag, Er:Yag) Laser Therapy on Incidence, Severity and Duration of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT). Prospective Randomized Open-label Study
|
N/A | |
| Recruiting |
NCT05629676 -
Virtual Reality Intervention for Patients Undergoing BMT
|
N/A | |
| Recruiting |
NCT05694910 -
Reiki Effects on Bone Marrow Transplant Patients
|
N/A | |
| Completed |
NCT05352789 -
Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey.
|
||
| Withdrawn |
NCT03963999 -
Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients
|
Phase 4 | |
| Recruiting |
NCT03865589 -
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
|
N/A |